Side-by-side comparison of AI visibility scores, market position, and capabilities
Bethesda MD global hotel franchisor (NASDAQ: MAR) ~$24.2B FY2024 revenue; 9,100+ hotels, Bonvoy 230M members, asset-light 60%+ EBITDA margins, Ritz-Carlton/Sheraton/Westin competing with Hilton and Hyatt.
Marriott International, Inc. is a Bethesda, Maryland-based global hospitality company — publicly traded on the NASDAQ (NASDAQ: MAR) as an S&P 500 Consumer Discretionary component — managing and franchising 30+ hotel and lodging brands across all price segments (luxury: Ritz-Carlton, St. Regis, EDITION, W Hotels; premium: Marriott, Sheraton, Westin, Renaissance, Le Méridien; select service: Courtyard, Fairfield, SpringHill Suites, Moxy; extended stay: Residence Inn, Element; timeshare: Marriott Vacations Worldwide) through approximately 377,000 associates at 9,100+ properties with 1.7 million rooms in 141 countries. In fiscal year 2024, Marriott reported revenues of approximately $24.2 billion and adjusted EBITDA of $5.1 billion (+9% year-over-year), driven by RevPAR (Revenue Per Available Room) growth in all global regions as leisure and business travel demand normalized post-COVID and international inbound travel to the United States reached recovery levels. CEO Anthony Capuano continues the asset-light franchise and management model that Marriott executed through the transformational 2016 acquisition of Starwood Hotels & Resorts Worldwide ($13.6 billion — the largest hotel acquisition in history, adding Sheraton, Westin, W, St. Regis, and Luxury Collection) — creating the world's largest hotel company by room count and establishing the Marriott Bonvoy loyalty program (230+ million enrolled members, the largest hotel loyalty program globally) as the central customer retention and engagement platform. Marriott's asset-light model (owning essentially no hotels — instead managing and franchising third-party owned properties) generates fee-based revenue (franchise fees, management base and incentive fees, Bonvoy licensing fees to franchisees) at 60%+ EBITDA margins with minimal capital expenditure requirements, creating one of the highest-margin hospitality business models possible.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.